18F-FLT and 18F-FDG PET imaging for patients with non-small cell lung cancer

18F-FLT and 18F-FDG PET imaging for patients with non-small cell lung cancer - 18F-FLT and 18F-FDG PET imaging for patients with non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010636

Enrollment

Registered

2013-05-02

Start date

2010-06-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

Patients undergo both 18F-FLT and 18F-FDG PET scan before and after 1 cycle of systemic chemotherapy.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Eligible patients are men and women aged 20 years or older with a diagnosis of non-small cell carcinoma.

Exclusion criteria

Exclusion criteria: Exclusion criteria; 1, Fasting serum glucose levels above 150 mg/dl. 2, Pregnant women. 3, Nursing women.

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of 18F-FLT and 18F-FDG PET	—

Secondary

Measure	Time frame
1, Overall survival after PET examination 2, Predictive value of 18F-FLT and 18F-FDG PET in patients with non-small cell lung cancer treated with systemic chemotherapy.	—

Countries

Japan

Contacts

Public ContactYukihiro Umeda

Faculty of Medical Sciences, University of Fukui Third Department of Internal Medicine

umeda@u-fukui.ac.jp0776-61-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026